Organisational changes at Covidien
This article was originally published in Scrip
Covidien has appointed Bryan Hanson group president with responsibility for the surgical devices and energy-based devices businesses, Peter Wehrly group president with responsibility for the respiratory and monitoring solutions and vascular therapies businesses and regional responsibility for Japan, and Michael Sgrignari senior vice-president of quality and operations. They have all been appointed from within Covidien, and will report to José Almeida, president of medical devices and CEO-elect. James Muse, senior vice-president of global supply chain and Scott Flora, president of surgical devices, have left the company.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.